Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in
subjects who previously participated in a GB002 PAH study.
Phase:
Phase 2
Details
Lead Sponsor:
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.